Skip to Content
Merck
  • Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.

Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.

Journal of medicinal chemistry (2008-06-19)
Paige E Mahaney, Lori K Gavrin, Eugene J Trybulski, Gary P Stack, T An Vu, Stephen T Cohn, Fei Ye, Justin K Belardi, Arthur A Santilli, Joseph P Sabatucci, Jennifer Leiter, Grace H Johnston, Jenifer A Bray, Kevin D Burroughs, Scott A Cosmi, Liza Leventhal, Elizabeth J Koury, Yingru Zhang, Cheryl A Mugford, Douglas M Ho, Sharon J Rosenzweig-Lipson, Brian Platt, Valerie A Smith, Darlene C Deecher
ABSTRACT

Further exploration of the cycloalkanol ethylamine scaffold, of which venlafaxine ( 1) is a member, was undertaken to develop novel and selective norepinephrine reuptake inhibitors (NRIs) for evaluation in a variety of predictive animal models. These efforts led to the discovery of a piperazine-containing analogue, 17g (WY-46824), that exhibited potent norepinephrine reuptake inhibition, excellent selectivity over the serotonin transporter, but no selectivity over the dopamine transporter. Synthesis and testing of a series of cyclohexanol ethylpiperazines identified ( S)-(-)- 17i (WAY-256805), a potent norepinephrine reuptake inhibitor (IC 50 = 82 nM, K i = 50 nM) that exhibited excellent selectivity over both the serotonin and dopamine transporters and was efficacious in animal models of depression, pain, and thermoregulatory dysfunction.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethylamine solution, 2.0 M in THF
Sigma-Aldrich
Ethylamine solution, 66.0-72.0% in H2O
Sigma-Aldrich
Ethylamine solution, 2.0 M in methanol